Elafibranor Drug Asset Due Diligence Report 2026

This Elafibranor Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Elafibranor can convert its Small molecule drug profile and PPARα x PPARδ biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Elafibranor (query alias: elafibranor)
Modality / target	Small molecule drug; PPARα x PPARδ; PPARα agonists, PPARδ agonists
Highest global status	Approved
Originator	Ipsen Biopharm Ltd.
Active developers	Ipsen SA, Ipsen Pharma SA, Ipsen Developments Ltd.

The MCP disease footprint includes Primary Biliary Cholangitis, Cholangitis, Sclerosing. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07387549	Phase 3	Recruiting	350	Event-Free Survival
NCT06730061	Phase 3	Active, not recruiting	18	Percentage of participants with Alkaline phosphatase (ALP) <1.67x ULN, ALP decrease ≥15% and Total Bilirubin (TB) ≤ ULN
JPRN-jRCT2011240053	Phase 3	Recruiting	18	Response to treatment at Week 52 defined as ALP <1.67xULN and TB <=ULN and ALP decrease >=15%

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Baseline Alkaline Phosphatase Impacts Response Rates in Primary Biliary Cholangitis: Exploring Response to Elafibranor in <scp>ELATIVE</scp>

Phase 3; n=468; evaluation: Positive. Reported fields: -; ALP normalization = 53.3 %

Safety and efficacy of elafibranor in primary sclerosing cholangitis: The ELMWOOD phase II randomized-controlled trial

Phase 2; n=68; evaluation: Positive. Reported fields: ALP = -54.7 U/L ; ALP = -35.3 U/L ; -

Ipsen’s elafibranor shows promise in rare liver disease primary sclerosing cholangitis

Phase 2; n=68; evaluation: Positive. Reported fields: AE = Data from ELMWOOD demonstrated a positive safety and tolerability profile. ; AE = Data from ELMWOOD demonstrated a positive safety and tolerability profile.

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Elafibranor addresses Primary Biliary Cholangitis, Cholangitis, Sclerosing. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2025-01-30	GENFIT Announces Completion of Non-dilutive Royalty Financing Agreement with HCRx and Results of Repurchase Offer to 2025 OCEANEs holders	Approved	US$135.2M upfront; US$57.2M milestones
2021-12-17	Ipsen and GENFIT Enter Into Exclusive Licensing Agreement for Elafibranor, a Phase III Asset Evaluated in Primary Biliary Cholangitis, as Part of a Long-Term Global Partnership	Phase 3	US$135.3M upfront; US$405.9M milestones; US$541.2M stated total
2019-06-24	Terns Pharmaceuticals Announces Exclusive Licensing and Collaboration Agreement with GENFIT to Develop and Commercialize Elafibranor in the Greater China Region	Phase 3	US$35.0M upfront; US$193.0M milestones; US$228.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Fixed dose combinations of integrin inhibitor with PPAR agonists”. The milestone feed surfaced a patent-application signal described as “Elafibranor for use for long-term treatment of primary biliary cholangitis”. The milestone feed surfaced a patent-application signal described as “Combination of an FGFR4 inhibitor with a PPAR agonist”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO